Invitation & Agenda: Orexo R&D Day on March 24

Rhea-AI Summary

Orexo (OTCQX: ORXOY / STO: ORX; symbol provided: ORXOF) invites investors, analysts and media to its R&D Day on March 24, 2026 in Stockholm. Management will outline updated strategy after the US Zubsolv divestment and present R&D priorities centred on the AmorphOX drug delivery platform.

Agenda highlights include sessions on AmorphOX applications, OX640 intranasal epinephrine, OX390 intranasal rescue medication and a prerecorded expert perspective on xylazine/medetomidine/fentanyl risks. Registration available via the company's R&D Day webpage.

UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026. The event will take place at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden.

During the day, CEO Nikolaj Sørensen and the management team will outline Orexo's updated strategy and R&D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The program will also feature expert perspectives from Mark A. Smith, PhD, Davidson College, NC, US, on emerging threats linked to xylazine, medetomidine, and fentanyl combinations.

The agenda is outlined below. To register for the event, please visit the R&D Day webpage:
https://www.orexo.se/rnd-day2026

 

Time am CET	Topic or activity	Presenter
9:00 – 9.30	Registration and coffee.
9:30 – 9:45	Shaping Orexo's future: Strategic priorities and value creation.	Nikolaj Sørensen,                        President and CEO.
9:45 – 10:00	AmorphOX: A unique opportunity to transform drug delivery of biomolecules from unstable injectables to convenient nasal or tablet delivery in an established scalable commercial supply chain.	Robert Rönn, SVP and Head of R&D/ Cecilia Coupland,                     SVP and Head of Operations.
10:00 – 10:15	AmorphOX: Moving beyond nasal delivery in GLP-1s and expanding into new areas with significant market needs through preclinical innovation, and strategic partnerships.	Robert Rönn, SVP and Head of R&D/ Lisa Moore, SVP, Product and Portfolio Strategy.
10:15-10:30	OX640: Aiming for the best-in-class nasal epinephrine product improving stability, bioavailability and patient convenience to address the needs of severe allergy patients.	Robert Rönn/ Lisa Moore.
10:30-10:45	Break.
10:45-11:00	OX390: Developing the world's first medical countermeasure (MCM) to the rising threat from xylazine and medetomidine in collaboration with BARDA, a center within the US Department of Health and Human Services.	Edward Kim, SVP and Chief Medical Officer.
11:00-11:15	Expert perspectives: Why counter-measures are needed for the emerging threats from xylazine, medetomidine, and fentanyl combinations.	Mark A. Smith, PhD  Davidson College, NC, US. Dr Smith will attend through a prerecorded video.
11:15-11:30	Building a viable business model through business development.	Fredrik Järrsten, EVP and CFO, Head of Business Development.
11:30-12:00	Q&A, incl closing remarks by CEO.	All presenters.
12 pm	Lunch & networking.

Notes: OX640 is a powder-based intranasal epinephrine product candidate in development for the emergency treatment of Type I allergic reactions; OX390 is a powder-based intranasal rescue medication candidate in development for adulterated overdoses. Neither product has been approved by any regulatory agency.

Minor changes may be made to the agenda ahead of the event.

For further information contact:
Lena Wange, IR and Communications Director
Tel: +46 (0)18 780 88 00, +46 73 064 16 36
Email: ir@orexo.com

About Orexo

Orexo is a Swedish pharmaceutical company dedicated to advance treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to route of administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm's main market and trades as ADRs on the OTCQX market in the United States.

For more information about Orexo visit, www.orexo.com. You can also follow Orexo on X, LinkedIn and YouTube.

The information was submitted for publication at 4 pm CET, on March 6, 2026.

CONTACT:

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/invitation---agenda--orexo-r-d-day-on-march-24,c4318007

View original content:https://www.prnewswire.com/news-releases/invitation--agenda-orexo-rd-day-on-march-24-302706888.html

SOURCE Orexo

FAQ

What will Orexo (ORXOF) present at its R&D Day on March 24, 2026?

Orexo will present an updated strategy and R&D priorities, focused on AmorphOX drug delivery and product candidates. According to Orexo, management and R&D leaders will explain how AmorphOX supports nasal and tablet delivery and outline OX640 and OX390 development plans.

What is AmorphOX and why does Orexo (ORXOF) emphasize it at the March 24 R&D Day?

AmorphOX is Orexo's proprietary drug-delivery technology aimed at converting unstable injectables into nasal or tablet formats. According to Orexo, the platform targets biomolecule stability and scalable commercial supply chains and is central to the company's post-divestment R&D focus.

What are OX640 and OX390 and how do they fit Orexo's pipeline (ORXOF)?

OX640 is a powder intranasal epinephrine candidate for severe allergy; OX390 is an intranasal rescue medication candidate for adulterated overdoses. According to Orexo, both are in development and neither product has been approved by any regulatory agency.

Is Orexo (ORXOF) working with BARDA on OX390 and what does that mean?

Orexo states OX390 is being developed as a medical countermeasure in collaboration with BARDA, a U.S. health agency center. According to Orexo, the collaboration targets rising threats from xylazine and medetomidine in adulterated overdoses and supports development efforts.

How can investors register to attend Orexo's R&D Day on March 24, 2026?

Investors, analysts and media can register via Orexo's dedicated R&D Day webpage. According to Orexo, the event is at the Royal Swedish Academy of Engineering Sciences in Stockholm and includes presentations, Q&A and a networking lunch.

Will experts discuss xylazine, medetomidine and fentanyl at Orexo's (ORXOF) R&D Day?

Yes, expert perspectives on threats from xylazine, medetomidine and fentanyl combinations are included in the agenda. According to Orexo, Mark A. Smith, PhD, provides a prerecorded expert segment explaining the need for countermeasures and clinical context.